My passion for innovative biomedical research, particularly in toxicology and novel drug development, drives my aspiration to join the Hong Kong Laureate Forum 2025. As an Honorary Senior Research Associate at The University of Hong Kong and CEO of BivaCoo Limited, I actively contribute to groundbreaking research aimed at addressing significant health challenges. My doctoral work on the toxicological evaluation of a novel anti-hypertensive compound, combined with my recent patent innovations utilizing pearl powder for detoxification, underscores my commitment to scientific advancements with practical health applications.

Participating in this esteemed Forum represents an unparalleled opportunity to engage with pioneering scientific minds, foster collaborations, and explore interdisciplinary research frontiers. I am particularly enthusiastic about contributing my expertise, gaining fresh insights from leading laureates, and leveraging these interactions to propel my work toward impactful innovations in health and biotechnology. Joining this vibrant intellectual community aligns perfectly with my professional ambitions, and I eagerly anticipate the transformative ideas and collaborative opportunities it promises.

My research primarily focuses on the comprehensive development and toxicological evaluation of KSD179019, an innovative anti-hypertensive small molecule designed to address global cardiovascular challenges. Employing a multidisciplinary approach, I combine advanced computational toxicology, in-depth biochemical assessments, and rigorous in vivo experimentation to establish the therapeutic efficacy, safety, and pharmacological mechanisms of KSD179019. My studies include systematic evaluations covering acute, sub-chronic, and chronic toxicity, contributing critical insights necessary for regulatory approval and clinical advancement.

Through collaborations with interdisciplinary teams, I have identified and characterized the compound’s therapeutic profile and potential side effects, ensuring robust preclinical validation. My recent publications in Food and Chemical Toxicology , have established KSD179019 as a promising therapeutic candidate with strong safety margins. Ultimately, my goal is to transition KSD179019 from laboratory innovation to clinical application, significantly improving treatment outcomes for patients suffering from hypertension. This research underscores my commitment to translational science, aiming to provide safer, more effective therapies, thereby reducing global cardiovascular disease burden.